🇺🇸 FDA
Patent

US 7253187

Heterocyclic inhibitors of ERK2 and uses thereof

granted A61PA61P1/16A61P11/00

Quick answer

US patent 7253187 (Heterocyclic inhibitors of ERK2 and uses thereof) held by Vertex Pharmaceuticals Incorporated expires Mon Aug 02 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Aug 07 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 02 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61P, A61P1/16, A61P11/00, A61P17/06, A61P19/00